Contraception
Volume 75, Issue 2 , Pages 136-141, February 2007

Fourteen-day safety and acceptability study of the universal placebo gel

  • Jill L. Schwartz

      Affiliations

    • CONRAD, Eastern Virginia Medical School (EVMS), Arlington, VA 22209, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 703 524 4744; fax: +1 703 524 4770.
  • ,
  • Susan A. Ballagh

      Affiliations

    • CONRAD, EVMS, Norfolk, VA 23507, USA
  • ,
  • Cynthia Kwok

      Affiliations

    • Family Health International, Research Triangle Park, NC 27713, USA
  • ,
  • Christine K. Mauck

      Affiliations

    • CONRAD, Eastern Virginia Medical School (EVMS), Arlington, VA 22209, USA
  • ,
  • Debra H. Weiner

      Affiliations

    • Family Health International, Research Triangle Park, NC 27713, USA
  • ,
  • William F. Rencher

      Affiliations

    • CONRAD, Eastern Virginia Medical School (EVMS), Arlington, VA 22209, USA
  • ,
  • Marianne M. Callahan

      Affiliations

    • CONRAD, Eastern Virginia Medical School (EVMS), Arlington, VA 22209, USA

Received 12 May 2006; received in revised form 9 August 2006; accepted 6 September 2006. published online 30 October 2006.

Abstract 

Objective

This study evaluated the effect of the so-called universal placebo compared to the polystyrene sulfonate (PSS) placebo on genital irritation.

Design

A single-center, Phase I, randomized, closed-label study was performed to evaluate the genital irritation of microbicide placebo gels. Thirty healthy, sexually abstinent women were randomly assigned to apply 3.5 mL of either the universal placebo or the PSS placebo gel intravaginally twice daily for 14 days.

Methods

Genital irritation was assessed by signs as seen on pelvic examination and colposcopy and reports of symptoms. Vaginal health was assessed by wet mounts, Gram stains for Nugent score and polymorphonuclear leukocytes, and semiquantitative vaginal cultures. Acceptability was assessed as reported on the follow-up questionnaire.

Results

The universal placebo was less irritating than the PSS placebo with a lower proportion of women experiencing signs and/or symptoms of genital irritation throughout follow-up (36% compared to 80%, p=.0253). The universal placebo was associated with few and mild genital symptoms, few and minor colposcopic findings and good vaginal health with no clinically significant changes in genital flora. Most participants found the feel of the universal placebo gel neutral or pleasant, and all participants found it odorless.

Conclusions

The universal placebo appeared safe and acceptable when used twice daily for 14 days. The strategy of creating a de novo inert universal placebo is a successful approach. The universal placebo is appropriate for use as a placebo gel in HIV prevention trials with microbicide candidates.

Keywords: Universal placebo, Microbicides, Hydroxyethylcellulose, Sorbic acid, K-Y Jelly, Sexually transmitted infection

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0010-7824(06)00355-6

doi:10.1016/j.contraception.2006.09.003

Contraception
Volume 75, Issue 2 , Pages 136-141, February 2007